Adagio Therapeutics Divulga Resumo da Atividade Neutralizante do ADG20 Contra Variantes do SARS-CoV-2 e Descreve Iniciativas para Abordar o Omicron
13 janv. 2022 19h30 HE
|
Adagio Therapeutics, Inc.
Publicações recentes de vários laboratórios independentes mostram que o ADG20 tem atividade neutralizante com potência comparável a outros anticorpos que retêm atividade contra o Omicron Múltiplos...
Adagio Therapeutics, SARS-CoV-2 변이에 대한 ADG20의 중화 활동 종합 보고 및 Omicron 대응 계획 발표
13 janv. 2022 19h30 HE
|
Adagio Therapeutics, Inc.
여러 독립 시험기관의 연구 결과, ADG20의 중화 활동 능력치는 Omicron 중화 활동 보유한 기타 항체에 필적할 수준 Omicron 및 기타 SARS-CoV-2 변이 가능성에 대처하기 위해 다각도로 노력 중 미국 매사추세츠주 월섬, Jan. 14, 2022 (GLOBE NEWSWIRE) -- 임상 단계 바이오 제약사로 팬데믹으로 변질 우려가...
Adagio Therapeutics、SARS-CoV-2変異株に対するADG20中和活性の概要とオミクロン株に対処するための取り組みを発表
13 janv. 2022 19h30 HE
|
Adagio Therapeutics, Inc.
複数の独立した研究機関による最近の発表によると、ADG20は、オミクロン株に対する活性を保持する他の抗体と同等の効力の中和活性を有する オミクロン株および将来発生する可能性のあるSARS-CoV-2変異株に対応するための複数の取り組みが実施されている マサチューセッツ州ウォルサム発, Jan. 14, 2022 (GLOBE NEWSWIRE) --...
Adagio Therapeutics résume l'activité neutralisante de l'ADG20 contre les variants du SARS-CoV-2 et décrit ses initiatives visant à contrer Omicron
13 janv. 2022 19h30 HE
|
Adagio Therapeutics, Inc.
Des publications récentes de plusieurs laboratoires indépendants montrent que l'ADG20 a une activité neutralisante présentant une puissance comparable à d'autres anticorps et qui reste active contre...
Adagio Therapeutics 總結 ADG20 對 SARS-CoV-2 變種的中和活性，並概述解決 Omicron 的計劃
13 janv. 2022 19h30 HE
|
Adagio Therapeutics, Inc.
最近由幾個獨立實驗室發表的刊物顯示 ADG20 具有可與其他抗體相比的效力，具有中和活性，並可保留對 Omicron 的活性 目前正在進行對 Omicron 和潛在未來 SARS-CoV-2 變種的多項努力 麻省沃爾瑟姆, Jan. 14, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI)...
Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron
12 janv. 2022 16h57 HE
|
Adagio Therapeutics, Inc.
Recent Publications by Several Independent Laboratories Show ADG20 Has Neutralizing Activity with Potency Comparable to Other Antibodies that Retain Activity Against Omicron Multiple Efforts Underway...
Adagio Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
06 janv. 2022 06h30 HE
|
Adagio Therapeutics, Inc.
WALTHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Adagio Therapeutics报告ADG20针对新冠病毒奥密克戎变种的体外中和活性降低
14 déc. 2021 12h58 HE
|
Adagio Therapeutics, Inc.
马萨诸塞州沃尔瑟姆, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc.（纳斯达克股票代码:...
Adagio Therapeutics Relata Redução na Atividade Neutralizante In Vitro do ADG20 Contra a Variante Omicron SARS-CoV-2
14 déc. 2021 12h58 HE
|
Adagio Therapeutics, Inc.
WALTHAM, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- A Adagio Therapeutics, Inc., (Nasdaq: ADGI) uma empresa biofarmacêutica de estágio clínico focada na descoberta, desenvolvimento e comercialização...
Adagio Therapeutics 報告 ADG20 對 Omicron SARS-CoV-2 變種的體外中和活性減少
14 déc. 2021 12h58 HE
|
Adagio Therapeutics, Inc.
麻省窩咸, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI) 是一家臨床階段的生物製藥公司，專門發現、開發和商業化具有疫情潛力的抗體解決方案，今天緊隨外部體外分析後提供更新，以評估 ADG20 對 Omicron SARS-CoV-2 變種的中和活性。透過...